GILEAD SCIENCES INC (GILD:NASDAQ)
$139.03 0.04 (0.0288%)
Analysed GILEAD SCIENCES INC (GILD:NASDAQ) News Sources
Morgan Stanley Boosts Gilead (GILD) Outlook on Updated Biopharma Models
13-04-2026
yahoo.com
Compugen Highlights AI-Driven IO Pipeline, Key Trial Timelines and Big Pharma Partnerships at Needham Conference
13-04-2026
marketbeat.com
Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks
13-04-2026
yahoo.com
Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration
12-04-2026
yahoo.com
Gilead price target raised to $175 from $171 at Morgan Stanley
11-04-2026
yahoo.com
Gilead’s Tubulis Deal Recasts Oncology Ambitions And HIV Reliance Risks
11-04-2026
yahoo.com
AHF Slams Gilead for Role in Florida AIDS Drug Crisis
10-04-2026
yahoo.com
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
10-04-2026
yahoo.com
RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders
10-04-2026
biopharmadive.com
Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline
10-04-2026
yahoo.com
What is the current price of GILEAD SCIENCES INC (GILD:NASDAQ)?
The current price of GILEAD SCIENCES INC (GILD:NASDAQ) is $139.03.
GILEAD SCIENCES INC (GILD:NASDAQ) absolute price change since previous trading day?
The absolute price change of GILEAD SCIENCES INC (GILD:NASDAQ) since the previous trading day is $0.04.
GILEAD SCIENCES INC (GILD:NASDAQ) percentage price change since previous trading day?
The percentage price change of GILEAD SCIENCES INC (GILD:NASDAQ) since the previous trading day is 0.0288%.
What is the most recent average sentiment score for GILEAD SCIENCES INC (GILD:NASDAQ)?
The most recent average sentiment score for GILEAD SCIENCES INC (GILD:NASDAQ) is 84 out of 100.
What is the most recent average sentiment for GILEAD SCIENCES INC (GILD:NASDAQ)?
The most recent sentiment for GILEAD SCIENCES INC (GILD:NASDAQ) is .
SEC-8K** Filing Available For GILEAD SCIENCES INC (GILD:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.